Paxman (PAX) DNB Carnegie Småbolagsdag summary

Company overview and mission

• Specializes in medtech cryotherapy to manage chemotherapy side effects, focusing on hair loss and developing solutions for peripheral neuropathy.

• Aims to provide global access to scalp cooling and neuropathy treatments, regardless of income or location.

• Operates in 60 markets, with the U.S. as the primary growth focus.

Growth, revenue, and market opportunity

• Achieved approximately 30% year-on-year growth over the past eight years, driven by U.S. market entry.

• Currently treats less than 1% of eligible global patients, indicating significant untapped potential.

• Revenue growth expected to accelerate with changes in the reimbursement landscape.

Industry evolution and patient impact

• Shift in cancer care from survival to holistic patient well-being, increasing demand for supportive care.

• Patient impact and team growth are key motivators; reimbursement challenges remain a primary frustration.